An umbrella review on treatments and therapeutic options for COVID-19
- Authors: SeyedAlinaghi S.1, Afsahi A.M.2, Molla A.3, Mirzapour P.1, Shahidi R.3, Siami H.4, Rad F.F.5, Abbaspour F.5, Mozafari N.3, Fakhredini K.6, Mehraeen E.7, Dadras O.8
-
Affiliations:
- Iranian Research Center for HIV/AIDS (IRCHA), Tehran University of Medical Sciences
- University of California
- Bushehr University of Medical Sciences
- Islamic Azad University
- Tehran University of Medical Sciences
- Behavioral Diseases Research Center, Health Institute, Kermanshah University of Medical Sciences
- Khalkhal University of Medical Sciences
- University of Bergen
- Issue: Vol 13, No 5 (2023)
- Pages: 885-898
- Section: ORIGINAL ARTICLES
- URL: https://journals.rcsi.science/2220-7619/article/view/158891
- DOI: https://doi.org/10.15789/2220-7619-AUR-15080
- ID: 158891
Cite item
Full Text
Abstract
Introduction. As the COVID-19 pandemic continues to pose a significant challenge to global health, effective therapeutic options for preventing and treating the disease have become increasingly important. We aimed to provide an update on current treatments and therapeutic options for COVID-19 patients. Materials and methods. The purpose of this umbrella review is to explore the current treatments and therapeutic options for COVID-19 patients. Keywords and their combinations were searched across online databases in Embase, PubMed/MEDLINE, Web of Science, and Scopus spanning from July 1, 2020, through March 3, 2023. Publications were selected for data extraction in two steps based on the study inclusion/exclusion criteria. The study adheres to the PRISMA checklist as well as NIH bias risk and quality assessment tool. Results. In this review, 28 relevant articles were selected for the final qualitative synthesis. The majority of included studies had reported on the efficacy of Lopinavir/Ritonavir (n = 4), Ivermectin (n = 3), Baricitinib (n = 2), Tocilizumab (n = 2), Remdesivir (n = 2), ACEI/ARB (n = 2), Vitamin D (n = 2), Molnupiravir (n = 2), Traditional Chinese medicine (TCM) (n = 2), Convalescent plasma transfusion (CPT) (n = 2) and hydroxychloroquine (n = 2) in treating COVID-19. It appeared that Baricitinib, Remdesivir, ACEI/ARB, TCM, and CPT may have beneficial effects on reducing mortality, hospitalization duration, and disease severity in COVID-19 patients. Other interventions, such as Lopinavir/Ritonavir, Ivermectin, Vitamin D, and Hydroxychloroquine did not show clear benefits or had inconclusive results. Conclusion. This umbrella review provides a comprehensive overview of the current evidence on the effectiveness and safety of various pharmacological and non-pharmacological interventions for COVID-19. These results provide an updated overview of the current landscape for COVID-19 treatments, highlighting potential avenues for further research and clinical practice. It is crucial to continue monitoring emerging evidence and conducting rigorous studies to guide the development and optimization of therapeutic strategies against COVID-19.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
SeyedAhmad SeyedAlinaghi
Iranian Research Center for HIV/AIDS (IRCHA), Tehran University of Medical Sciences
Email: s_a_alinaghi@yahoo.com
MD, MPhil, PhD, Clinical Epidemiologist, Associate Professor, Research Deputy
Iran, Islamic Republic of, TehranAmir M. Afsahi
University of California
Email: amir.masoud.afsahi@gmail.com
MD, PhD, Department of Radiology, School of Medicine
United States, San DiegoAyoob Molla
Bushehr University of Medical Sciences
Email: Ayoob.dpt87@gmail.com
MD Student, School of Medicine
Iran, Islamic Republic of, BushehrPegah Mirzapour
Iranian Research Center for HIV/AIDS (IRCHA), Tehran University of Medical Sciences
Email: pegah.mirzapour@yahoo.com
Iranian Research Center for HIV/AIDS (IRCHA)
Iran, Islamic Republic of, TehranRamin Shahidi
Bushehr University of Medical Sciences
Email: dr.raminshahidi1@gmail.com
MD, School of Medicine
Iran, Islamic Republic of, BushehrHaleh Siami
Islamic Azad University
Email: Haleh.siami@gmail.com
MD student, School of Medicine
Iran, Islamic Republic of, TehranFarid F. Rad
Tehran University of Medical Sciences
Email: farid.f.rad@gmail.com
MD student, School of Medicine
Iran, Islamic Republic of, TehranFaeze Abbaspour
Tehran University of Medical Sciences
Email: absprfaeze@gmail.com
School of Medicine
Iran, Islamic Republic of, TehranNavid Mozafari
Bushehr University of Medical Sciences
Email: navidmozaffari97@gmail.com
School of Medicine
Iran, Islamic Republic of, BushehrKamal Fakhredini
Behavioral Diseases Research Center, Health Institute, Kermanshah University of Medical Sciences
Email: fakhredini1@gmail.com
PhD, MD student
Iran, Islamic Republic of, KermanshahEsmaeil Mehraeen
Khalkhal University of Medical Sciences
Author for correspondence.
Email: es.mehraeen@gmail.com
PhD, Assistant Professor, Department of Health Information Technology
Iran, Islamic Republic of, KhalkhalOmid Dadras
University of Bergen
Email: omiddadras@yahoo.com
MD, Dr.PH, Bergen Addiction Research, Department of Addiction Medicine
Norway, BergenReferences
- Albuquerque A.M., Eckert I., Tramujas L., Butler-Laporte G., McDonald E.G., Brophy J.M., Lee T.C. Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis. Clin. Microbiol. Infect. 2023, vol. 29, no. 1, pp. 13–21. doi: 10.1016/j.cmi.2022.07.008
- Amstutz A., Speich B., Mentré F., Rueegg C.S., Belhadi D., Assoumou L., Burdet C., Murthy S., Dodd L.E., Wang Y., Tikkinen K.A.O., Ader F., Hites M., Bouscambert M., Trabaud M.A., Fralick M., Lee T.C., Pinto R., Barratt-Due A., Lund-Johansen F., Müller F., Nevalainen O.P.O., Cao B., Bonnett T., Griessbach A., Taji Heravi A., Schönenberger C., Janiaud P., Werlen L., Aghlmandi S., Schandelmaier S., Yazdanpanah Y., Costagliola D., Olsen I.C., Briel M. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet Respir. Med., 2023, vol. 11, no. 5, pp. 453–464. doi: 10.1016/S2213-2600(22)00528-8
- Ansems K., Grundeis F., Dahms K., Mikolajewska A., Thieme V., Piechotta V., Metzendorf M.I., Stegemann M., Benstoem C., Fichtner F. Remdesivir for the treatment of COVID-19. Cochrane Database Syst. Rev., 2021, vol. 8, no. 8: CD014962. doi: 10.1002/14651858.CD014962
- Areri H., Marshall A., Harvey G. Factors influencing self-management of adults living with HIV on antiretroviral therapy in Northwest Ethiopia: a cross-sectional study. BMC Infect. Dis., 2020, vol. 20, no. 1: 879. doi: 10.1186/s12879-020-05618-y
- Celotto S., Veronese N., Barbagallo M., Ometto F., Smith L., Pardhan S., Barnett Y., Ilie P.C., Soysal P., Lagolio E., Kurotschka P.K., Tonelli R., Demurtas J. An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy. Int. J. Infect. Dis., 2021, vol. 103, pp. 599–606. doi: 10.1016/j.ijid.2020.12.018
- Cheema H.A., Sohail A., Fatima A., Shahid A., Shahzil M., Ur Rehman M.E., Awan R.U., Chinnam S., Nashwan A.J. Quercetin for the treatment of COVID-19 patients: a systematic review and meta-analysis. Rev. Med. Virol., 2023, vol. 33, no. 2: e2427. doi: 10.1002/rmv.2427
- Chinta S., Rodriguez-Guerra M., Shaban M., Pandey N., Jaquez-Duran M., Vittorio T.J. COVID-19 therapy and vaccination: a clinical narrative review. Drugs Context, 2023, vol. 12: 2022-7-2. doi: 10.7573/dic.2022-7-2
- Dahms K., Mikolajewska A., Ansems K., Metzendorf M.I., Benstoem C., Stegemann M. Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis. Eur. J. Med. Res., 2023, vol. 28, no. 1: 100. doi: 10.1186/s40001-023-01072-z
- Deng J., Rayner D., Ramaraju H.B., Abbas U., Garcia C., Heybati K., Zhou F., Huang E., Park Y.J., Moskalyk M. Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis. Clin. Microbiol. Infect., 2023, vol. 29, no. 5, pp. 578–586. doi: 10.1016/j.cmi.2023.01.010
- Dhawan M., Priyanka, Parmar M., Angural S., Choudhary O.P. Convalescent plasma therapy against the emerging SARS-CoV-2 variants: delineation of the potentialities and risks. Int. J. Surg., 2022, vol. 97: 106204. doi: 10.1016/j.ijsu.2021.106204
- Feiner Solís Á., Avedillo Salas A., Luesma Bartolomé M.J., Santander Ballestín S. The effects of Vitamin D supplementation in COVID-19 patients: a systematic review. Int. J. Mol. Sci., 2022, vol. 23, no. 20: 12424. doi: 10.3390/ijms232012424
- Giles G., Varghese S., Shymko G., Nguyen T., Waters F. Clozapine therapy and COVID-19: a systematic review of the prevalence rates, health outcomes, hematological markers, and patient perspectives. Schizophr Bull., 2023, vol. 49, no. 1, pp. 53–67. doi: 10.1093/schbul/sbac148
- Greene C., Wilson J., Griffin H., Tingle A., Cooper T., Semple M.G., Enoch D., Lee A., Loveday H. The role of pandemic planning in the management of COVID-19 in England from an infection prevention and control perspective: results of a national survey. Public Health., 2023, vol. 217, pp. 89–94. doi: 10.1016/j.puhe.2023.01.028
- Hayden M.K., Hanson K.E., Englund J.A., Lee F., Lee M.J., Loeb M., Morgan D.J., Patel R., El Alayli A., El Mikati I.K., Sultan S., Falck-Ytter Y., Mansour R., Amarin J.Z., Morgan R.L., Murad M.H., Patel P., Bhimraj A., Mustafa R.A. The Infectious Diseases Society of America Guidelines on the diagnosis of COVID-19: antigen testing. Clin. Infect. Dis., 2023: ciad032. doi: 10.1093/cid/ciad032
- Huang N.X., Yuan Q., Fang F., Yan B.P., Sanderson J.E. Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19. PLoS One, 2023, vol. 18, no. 1: e0280280. doi: 10.1371/journal.pone.0280280
- Kramer A., Prinz C., Fichtner F., Fischer A.L., Thieme V., Grundeis F., Spagl M., Seeber C., Piechotta V., Metzendorf M.I., Golinski M., Moerer O., Stephani C., Mikolajewska A., Kluge S., Stegemann M., Laudi S., Skoetz N. Janus kinase inhibitors for the treatment of COVID-19. Cochrane Database Syst. Rev., 2022, vol. 6, no. 6: CD015209. doi: 10.1002/14651858.CD015209
- Kurniawati D.R., Subagjo A., Djuari L. Efficacy and safety of prophylactic-dose anticoagulation therapy with intermediate-therapeutic doses in COVID-19 patients. Indian Journal of Forensic Medicine & Toxicology, 2023, vol. 17, no. 1, pp. 97–101, doi: 10.37506/ijfmt.v17i1.18902
- Li Y., Qin Y., Chen N., Ge L., Wang Q., Aboudou T., Han J., Hou L., Cao L., Li R., Li M., Mi N., Xie P., Wu S., Hu L., Li X., Song Z., Ji J., Zhang Z., Yang K. Use of traditional Chinese medicine for the treatment and prevention of COVID-19 and rehabilitation of COVID-19 patients: an evidence mapping study. Front. Pharmacol., 2023, vol. 14: 1069879. doi: 10.3389/fphar.2023.1069879
- Liang W., Liang H., Ou L., Chen B., Chen A., Li C., Li Y., Guan W., Sang L., Lu J., Xu Y., Chen G., Guo H., Guo J., Chen Z., Zhao Y., Li S., Zhang N., Zhong N., He J. China Medical Treatment Expert Group for COVID-19. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern. Med., 2020, vol. 180, no. 8, pp. 1081–1089. doi: 10.1001/jamainternmed.2020.2033
- Liu Q., Fu W., Zhu C.J., Ding Z.H., Dong B.B., Sun B.Q., Chen R.C. Effect of continuing the use of renin-angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis. BMC Infect. Dis., 2023, vol. 23, no. 1: 53. doi: 10.1186/s12879-023-07994-7
- Luo X., Zhang Y., Li H., Ren M., Liu Y., Liu Y., Zhang Y., Kuang Z., Cai Y., Chen Y., Ni X. Clinical evidence on the use of Chinese herbal medicine for acute infectious diseases: an overview of systematic reviews. Front. Pharmacol., 2022, vol. 13: 752978. doi: 10.3389/fphar.2022.752978
- Maideen N.M.P., Balasubramanian R., Manavalan G., Balasubramanian K., Subramanian N., Murugesan T., Solaimalai V.K. An insight of clinical evidence of ayurveda interventions in the management of COVID-19 patients. Infect. Disord. Drug Targets, 2022, vol. 22, no. 6: e210322202491. doi: 10.2174/1871526522666220321152504
- Mali K.R., Eerike M., Raj G.M., Bisoi D., Priyadarshini R., Ravi G., Chaliserry L.F., Janti S.S. Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review. Ir. J. Med. Sci., 2023, vol. 192, no. 4, pp. 1665–1678. doi: 10.1007/s11845-022-03139-y
- Mehraeen E., Najafi Z., Hayati B., Javaherian M., Rahimi S., Dadras O., SeyedAlinaghi S., Ghadimi M., Sabatier J.M. Current treatments and therapeutic options for COVID-19 patients: a systematic review. Infect. Disord. Drug Targets, 2022, vol. 22, no. 1: e260721194968. doi: 10.2174/1871526521666210726150435
- Mehraeen E., Oliaei S., SeyedAlinaghi S., Karimi A., Mirzapour P., Afsahi A.M., Barzegary A., Vahedi F., Soleymanzadeh M., Behnezhad F., Javaherian M., Zargari G., Mirghaderi S.P., Noori T., Sabatier J.M. COVID-19 in pediatrics: a systematic review of current knowledge and practice. Infect. Disord. Drug Targets, 2022, vol. 22, no. 5: e290921196908. doi: 10.2174/1871526521666210929121705
- Migliorini F., Vaishya R., Eschweiler J., Oliva F., Hildebrand F., Maffulli N. Vitamins C and D and COVID-19 susceptibility, severity and progression: an evidence based systematic review. Medicina (Kaunas), 2022, vol. 58, no. 7: 941. doi: 10.3390/medicina58070941
- Mohseni M., Ameri H., Arab-Zozani M. Potential limitations in systematic review studies assessing the effect of the main intervention for treatment/therapy of COVID-19 patients: an overview. Front. Med. (Lausanne), 2022, vol. 9: 966632. doi: 10.3389/fmed.2022.966632
- Morishita M., Hojo M. Treatment options for patients with severe COVID-19. Glob. Health Med., 2023, vol. 5, no. 2, pp. 99–105. doi: 10.35772/ghm.2023.01024
- Mousavi S., Zare S., Mirzaei M., Feizi A. Novel drug design for treatment of COVID-19: a systematic review of preclinical studies. Can. J. Infect. Dis. Med. Microbiol., 2022, vol. 2022: 2044282. doi: 10.1155/2022/2044282
- Niranjan A.K., Patel S.K., Channabasappa N.K., Rana J., Agrawal A., Kumar R., Pandey M.K., Tiwari S.P., Singh D.R. Resurgence of cholera in the COVID-19 era: a global health concern. Ann. Med. Surg. (Lond.), 2023, vol. 85, no. 4, pp. 1321–1322. doi: 10.1097/MS9.0000000000000415
- Pahari K.P., Vyas S., Aman S., Singh U., Singh P.K., Tiwari R., Dhanawat M., Therapeutic options for the treatment of 2019-novel Coronavirus in India: a review. Coronaviruses, 2022, vol. 3, no. 2: e041220188720. doi: 10.2174/2666796701999201204115545
- Pantsari T., Ali M.M., Ghouri M.H., Alharbi A.M., Alfahemi H. Role of antiviral drugs in management of mild and moderate Coronavirus disease-19: a systematic review. Adv. Life Sci. 2022, vol. 9, no. 3, pp. 270–276
- Paraskevas T., Kantanis A., Karalis I., Michailides C., Karamouzos V., Koniari I., Pierrakos C., Velissaris D. N-acetylcysteine efficacy in patients hospitalized with COVID-19 pneumonia: a systematic review and meta-analysis. Rom. J. Intern. Med., 2023, vol. 61, no. 1, pp. 41–52. doi: 10.2478/rjim-2023-0001
- Pashaei Z., SeyedAlinaghi S., Qaderi K., Barzegary A., Karimi A., Mirghaderi S.P., Mirzapour P., Tantuoyir M.M., Dadras O., Ali Z., Voltarelli F., Mehraeen E. Prenatal and neonatal complications of COVID-19: a systematic review. Health Sci. Rep., 2022, vol. 5, no. 2: e510. doi: 10.1002/hsr2.510
- Patel T.K., Patel P.B., Barvaliya M., Saurabh M.K., Bhalla H.L., Khosla P.P. Efficacy and safety of lopinavir-ritonavir in COVID-19: a systematic review of randomized controlled trials. J. Infect. Public Health, 2021, vol. 14, no. 6, pp. 740–748. doi: 10.1016/j.jiph.2021.03.015
- Popp M., Reis S., Schießer S., Hausinger R.I., Stegemann M., Metzendorf M.I., Kranke P., Meybohm P., Skoetz N., Weibel S. Ivermectin for preventing and treating COVID-19. Cochrane Database Syst. Rev., 2022, vol. 6, no. 6: 015017. doi: 10.1002/14651858.CD015017.pub3
- RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, 2020, vol. 396, no. 10259, pp. 1345–1352. doi: 10.1016/S0140-6736(20)32013-4
- Reis S., Metzendorf M.I., Kuehn R., Popp M., Gagyor I., Kranke P., Meybohm P., Skoetz N., Weibel S. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. Cochrane Database Syst. Rev., 2022, vol. 9, no. 9: 015395. doi: 10.1002/14651858.CD015395.pub2
- Sanghavi D., Bansal P., Kaur I.P., Mughal M.S., Keshavamurthy C., Cusick A., Schram J., Yarrarapu S.N.S., Giri A.R., Kaur N., Moreno Franco P., Abril A., Aslam F. Impact of colchicine on mortality and morbidity in COVID-19: a systematic review. Ann. Med., 2022, vol. 54, no. 1, pp. 775–789. doi: 10.1080/07853890.2021.1993327
- SeyedAlinaghi S., Karimi A., Barzegary A., Mojdeganlou H., Vahedi F., Mirghaderi S.P., Shobeiri P., Ramezani M., Yousefi Konjdar P., Mirzapour P., Tantuoyir M.M., Mehraeen E., Dadras O., Voltarelli F. COVID-19 mortality in patients with immunodeficiency and its predictors: a systematic review. Eur. J. Med. Res., 2022, vol. 27, no. 1: 195. doi: 10.1186/s40001-022-00824-7
- Shang W., Zhang B., Ren Y., Wang W., Zhou D., Li Y. Thymosin alpha1 use in adult COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Int. Immunopharmacol., 2023, vol. 114: 109584. doi: 10.1016/j.intimp.2022.109584
- Shibeeb S., Ajaj I., Al-Jighefee H., Abdallah A.M. Effectiveness of convalescent plasma therapy in COVID-19 patients with hematological malignancies: a systematic review. Hematol. Rep., 2022, vol. 14, no. 4, pp. 377–388. doi: 10.3390/hematolrep14040052
- Singh A.K., Singh A., Singh R., Misra A. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19. Diabetes Metab. Syndr., 2022, vol. 16, no. 2: 102396. doi: 10.1016/j.dsx.2022.102396
- Singh A.K., Singh A., Singh R., Misra A. Molnupiravir in COVID-19: a systematic review of literature. Diabetes Metab. Syndr., 2021, vol. 15, no. 6: 102329. doi: 10.1016/j.dsx.2021.102329
- Van De Laar C.J., Oude Voshaar M.A.H., Fakhouri W.K.H., Zaremba-Pechmann L., De Leonardis F., De La Torre I., Van De Laar M.A.F.J. Cost-effectiveness of a JAK1/JAK2 inhibitor vs a biologic disease-modifying antirheumatic drug (bDMARD) in a treat-to-target strategy for rheumatoid arthritis. Clinicoecon Outcomes Res., 2020, vol. 12, pp. 213–222. doi: 10.2147/CEOR.S231558
- Wei Q., Lin H., Wei R.G., Chen N., He F., Zou D.H., Wei J.R. Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis. Infect. Dis. Poverty, 2021, vol. 10. no. 1: 71. doi: 10.1186/s40249-021-00857-w
- Yang S., Shen S., Hou N. Is Ivermectin effective in treating COVID-19? Front. Pharmacol., 2022, vol. 13: 858693. doi: 10.3389/fphar.2022.858693